Despite childhood vaccination efforts and antiviral medications, the rate of Hepatitis B infection remains constant in the U.S. with the CDC estimating over 20,000 acute infections each year and over 800,000 people living with chronic HBV infection.
The World Health Organization estimates the global number of chronic HBV infections at over 250 million, with most infections in endemic areas occurring from mother to child at birth before a vaccination can be effective.
While life-long antiviral medications can control the replication of the Hepatitis B virus, and slow the unrelenting progression of ongoing liver damage, these life-long therapies do not reduce the HBV related risk of developing liver cancer – which is 100 times more likely to occur in patients with chronic Hepatitis B, than in individuals without the disease. The Hepatitis B Foundation reports that 25% – 40% of all patients with chronic HBV will develop liver cancer.
Curing this large human reservoir of chronically infected people is crucial to reducing HBV-associated morbidities and mortalities.
Seraph Research Institute is spearheading efforts to eradicate Hepatitis B with a novel and proprietary mechanism of action that directly targets the virus at its source. Unlike current antiviral medications, which slow or halt viruses replication, our scientists have achieved a breakthrough that has been shown in our studies to completely destroy the viral blueprints in the liver.